Xoma Royalty's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Xoma Royalty (XOMA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Xoma Royalty vs Its Competitors
- TTM: Trailing 12-month revenue of 49M vs 595,798M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.5% annualized vs trailing 12 months), vs decelerating (-6.9%) for its tracked peer group.
- Growth: Xoma Royalty generated -22.6% revenue growth year over year in Q1 2026, vs 12.7% for its competitors combined.
- Profitability: Its 17.2% net margin compares with 12.3% for the peer group.
- Peer revenue share: Xoma Royalty accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $3.47M compares with $0.99M for the peer group (3.5x).
- Structure: Xoma Royalty operates in the following segments: Single Reportable Segment; and reports the following subsidiaries: Generation Bio Co (competes with Arrowhead Pharmaceuticals Inc , Editas Medicine Inc , Nurix Therapeutics Inc ), Hillevax Inc (competes with Icon Plc, Moderna Inc , Vaxart Inc ), Mural Oncology Plc (competes with Werewolf Therapeutics Inc ), Turnstone Biologics Corp (competes with Werewolf Therapeutics Inc , Sana Biotechnology Inc , Instil Bio Inc ).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
XOMA Sales vs. its Competitors, Q1 2026
Xoma Royalty reported revenue contraction of 22.59 % year on year in Q1 2026, below its competitors' combined revenue growth of 12.73 %.
With a net margin of 17.22 %, Xoma Royalty achieved higher profitability than its competitors (12.33 %).
Xoma Royalty generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.
API endpoints for this dataset
Xoma Royalty vs. its Competitors, Q1 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Xoma Royalty reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Xoma Royalty and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Xoma Royalty Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (18) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Xoma Royalty's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -22.6% for Xoma Royalty. Xoma Royalty's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Xoma Royalty's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Xoma Royalty Corporation | Yes | Yes | Yes | No |
| Competitors combined (191) | ||||
| High-Confidence Competitors (21) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
XOMA Stock Performance relative to its Competitors
XOMA Stock Performance relative to High-Confidence Competitors
XOMA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Erasca Inc | 282.9% | Outperformed |
| 4 | Climb Bio Inc | 282.9% | Outperformed |
| 5 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Xoma Royalty's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Xoma Royalty's Comment on Competition and Industry Peers
Publicly Traded Peers of Xoma Royalty Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Xoma Royalty Corporation |
699.64 | 48.56 |
 Eli Lilly And Company |
1,279,607.89 | 86,462.00 |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Abbvie Inc |
520,773.08 | 66,014.00 |
 Merck and Co Inc |
365,658.80 | 66,569.00 |
 Novartis Ag |
319,173.30 | 56,674.00 |
| SUBTOTAL | 5,081,379.12 | 802,239.22 |
Sign in to see all competitors of Xoma Royalty Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Xoma Royalty Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Xoma Royalty's Competitors Named by the Company
Competitive relationships identified from Xoma Royalty reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Instil Bio Inc | Company report | 85% |
| Prime Medicine, Inc. | Company report | 85% |
| Moderna, Inc. | Company report | 85% |
| Monte Rosa Therapeutics, Inc. | Company report | 85% |
| Wave Life Sciences Ltd. | Company report | 85% |
| bevacizumab | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Kymera Therapeutics, Inc. | Company report | 85% |
| Icon Genetics | Company report | 85% |
| PARP | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Nurix Therapeutics, Inc. | Company report | 85% |
| China National Biotec | Company report | 85% |
| Cohort 4 of ARTISTRY-6 | Company report | 85% |
| argenx SE | Company report | 85% |
| Vaxart | Company report | 85% |
| pembrolizumab | Company report | 85% |
| Alnylam Pharmaceuticals, Inc. | Company report | 85% |
| Capstan Therapeutics Inc. | Company report | 85% |
| Orna Therapeutics, Inc. | Company report | 85% |
| Chongqing Zhifei Biological | Company report | 85% |
| nemvaleukin | Company report | 85% |
| Arrowhead Pharmaceuticals, Inc. | Company report | 85% |
| Hoffmann La Roche Ltd. | Company report | 85% |
| Janssen | Company report | 85% |
| Beam Therapeutics Inc. | Company report | 85% |
| iECURE, Inc. | Company report | 85% |
| Tessera Therapeutics, Inc. | Company report | 85% |
| Sonnet | Company report | 85% |
| CRISPR Therapeutics AG | Company report | 85% |
| Editas Medicine, Inc. | Company report | 85% |
| Intellia Therapeutics, Inc. | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Q32 Bio Inc | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Regenxbio Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Xoma Royalty's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Xoma Royalty's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Xoma Royalty Corporation | Single Reportable Segment 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Xoma Royalty Corporation.
Xoma Royalty's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Xoma Royalty Corporation | 700 | 3,468,214 | 1,423,714 |
| Eli Lilly And Company | 1,279,608 | 1,729,240 | 551,594 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Abbvie Inc | 520,773 | 1,158,140 | 181,509 |
| Merck and Co Inc | 365,659 | 887,587 | 42,267 |
| Novartis Ag | 319,173 | 752,973 | 185,566 |
| PEERS TOTAL | 5,080,679 | 994,891 | 137,086 |
Sign in to see all peers for Xoma Royalty Corporation.
Xoma Royalty's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Xoma Royalty Corporation | CH 54.36 % |
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Pfizer Inc | United States 63.93 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Xoma Royalty Corporation.
Xoma Royalty's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Xoma Royalty's industry classification, broader than the peer set above. Market cap in millions of $.Xoma Royalty ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 983, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,410 | 23.79 % |
| 2 | Johnson and Johnson | 688,169 | 12.92 % |
| 3 | Abbvie Inc | 519,284 | 9.75 % |
| 4 | Merck and Co Inc | 364,892 | 6.85 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Xoma Royalty Corporation | 700 | 0.00 % |
Market cap and industry share for the rest of Xoma Royalty's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-21.
Xoma Royalty's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.92 % (avg) | -37.9 pp |
| Operating Margin | 10.25 % | industry median | +9.2 pp |
| EBITDA Margin | 95.54 % | -6.30 % (avg) | +101.8 pp |
| Capital Intensity (Capex / Revenue) | 42.68 % | 7.51 % (avg) | +35.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Xoma Royalty's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 17.1x | 26.5x | -9.5x |
| EV / EBITDA | 10.8x | 15.4x | -4.6x |
| P/B | 5.5x | 4.2x | +1.3x |
| Return on Equity | 23.64 % | industry aggregate | 6.83 % |
| Return on Invested Capital | 1.52 % | -9.78 % (avg) | 11.30 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Xoma Royalty's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | -89.94 % | 246.67 % | - | - | -21.06 % | 498.72 % | 83.06 % |
| Operating Margin | 32.32 % | -318.12 % | -21.15 % | - | 57.79 % | - | - | 21.83 % |
| Return on Invested Capital | 269.58 % | -32.97 % | -3.76 % | - | 17.94 % | -17.61 % | -15.70 % | 3.80 % |
| P/E | 120.7x | - | - | - | 24.7x | - | - | 22.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Xoma Royalty's Strategic Group Map
Xoma Royalty is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Xoma Royalty's trailing-12-month revenue growth of 13.2% and operating margin of 10.3% compares with an average of 13.2% growth and 10.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Xoma Royalty sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Xoma Royalty's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 983 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 42.68 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Xoma Royalty's dedicated Suppliers and Customers pages, not here.
Xoma Royalty's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Xoma Royalty falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Xoma Royalty's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 9.2 points above the industry median.
- Return on equity 6.8 points above the industry aggregate.
Weaknesses
No rule matched.
Opportunities
- Trades at a lower P/E than the industry average (17.1x vs 26.5x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (54.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-6.9% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Xoma Royalty's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Xoma Royalty Corporation | 2.45 | 3.84 | 1.29 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Xoma Royalty Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Xoma Royalty's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Xoma Royalty Corporation | Q1 2026 | -22.6 % | +200.9 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +9.8 % | +11.8 % |
Sign in to see all peers for Xoma Royalty Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Xoma Royalty's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Xoma Royalty Corporation | Q1 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Xoma Royalty Corporation.
Xoma Royalty's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Xoma Royalty Corporation | 7.73% | 8.19% | 23.64% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Xoma Royalty Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Xoma Royalty's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Xoma Royalty Corporation | 25.59 | 14.41 |
| Eli Lilly And Company | 46.50 | 14.80 |
| Johnson and Johnson | 42.48 | 6.92 |
| Abbvie Inc | 50.58 | 7.89 |
| Merck and Co Inc | 119.39 | 5.49 |
| Novartis Ag | 22.82 | 5.63 |
| PEERS AVERAGE | 45.96 | 6.33 |
Sign in to see all peers for Xoma Royalty Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.